Denosumab (standard dosing) clinical trials

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

This study is looking at whether a medicine called Denosumab can work just as well when given less often (every 12 weeks instead of every 4 weeks) for people with breast or prostate cancer that has spread to their bones. We want to see if we can reduce side effects and costs without losing its benefits.